



INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)	Application Number	09/859,604
	Filing Date	May 17, 2001
	First Named Inventor	Jack R. Wands
	Group Art Unit	Not yet assigned
	Examiner Name	Not yet assigned
	Attorney Docket Number	21486-032CIP

U.S. PATENT DOCUMENTS							
Exam Initials	Cite No.	U.S. Patent Document No.	Issue Date	Name of Patentee(s) or Applicant(s)	Class	Sub Class	Filing Date If Appropriate
KAC	AA	6,165,464	12/26/00	Hudziak, et al.	424	142.1	

FOREIGN PATENT DOCUMENTS					
Exam Initials	Cite No.	Foreign Patent Document Office Number	Name of Patentee(s) or Applicant(s)	Date of Publication	Translation Yes No

OTHER NON PATENT LITERATURE DOCUMENTS			
Exam Initials	Cite No.	Name of Author, Title (when appropriate), Publication, Volume, Page(s), Date, Etc.	
KAC	CA	Aster J. et al., "Functional Analysis of the TAN-1 Gene, a Human Homolog of Drosophila Notch", Cold Spring Harb. Symp. Uant. Biol., 1994; 59:125-36.	
	CB	Baron et al., "Insulin Receptor-Induced Phosphorylation of Cellular and Synthetic Substrates Is Regulated by the Receptor β -Subunit C-Terminus", Endocrinology, 1996 August; 137(8) 3416-23.	
	CC	Boder, et al., "Directed Evolution of Antibody Fragments with Monovalent Femtomolar Antigen-Binding Affinity", PNAS, September 26, 2000, vol. 97 (20), 10701-10705.	
	CD	Branch, "A hitchhikers guide to antisense and nonantisense biochemical pathways", Hepatology, Vol. 24, 1996, pp. 1517-1529.	
	CE	Broadus et al., "Strategies for the design and delivery of antisense oligonucleotides in central nervous system", Methods in Enzymology, 2000, Vol. 314, pp. 121-135.	
	CF	Capobianco et al., "Neoplastic Transformation by Truncated Alleles of Human NOTCH1/TAN1 and NOTCH2", 1997, Mol. Cell Biol. 17:6265-6273	
	CG	Czubayko et al., "Ribozyme-targeting Elucidates a Direct Role of Pleiotrophin in Tumor Growth", 1994, J. Biol. Chem. 269:21358-21363	
	CH	de la Monte et al., "Microtiter Immunocytochemical ELISA Assay," 1999, Biotechniques	
	CI	de la Monte SM, et al., "Differential Effects of Ethanol on Insulin-Signaling Through the Insulin Receptor Substrate-1", Alcohol Clin. Exp. Res., 1999 May; 23(5):770-7.	
	CJ	Dinchuk, et al., "Aspartyl β -Hydroxylase (Asph) and an Evolutionarily Conserved Isoform of Asph Missing the Catalytic Domain Share Exons with Junctin," (2000) 275, 39543-54	
	CK	Foote, et al., "Breaking the Affinity Ceiling for Antibodies and T Cell Receptors", PNAS, September 26, 2000, vol.97(20), 10679-10681.	
	CL	GENBANK Accession No. S83325	
	CM	GENBANK Accession No. JS0670	
	CN	GENBANK Accession No. NM 005544	
✓	CO	Ghose et al., "Immunochemical Techniques, part F, Conventional Antibodies Fc Receptors and Cytotoxicity", Methods in Enzymology, Vol. 93, 326-327, 1983	
Examiner Signature		<i>Karen A. Gaudin</i>	Date Considered 6/13/03

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered.

Include copy of this form with next communication to applicant.



Modified Form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)	Application Number	09/859,604
	Filing Date	May 17, 2001
	First Named Inventor	Jack R. Wands
	Group Art Unit	Not yet assigned
	Examiner Name	Not yet assigned
	Attorney Docket Number	21486-032CIP

U.S. PATENT DOCUMENTS							
Exam Initials	Cite No.	U.S. Patent Document No.	Issue Date	Name of Patentee(s) or Applicant(s)	Class	Sub Class	Filing Date If Appropriate

OTHER NON PATENT LITERATURE DOCUMENTS		
Exam Initials	Cite No.	Name of Author, Title (when appropriate), Publication, Volume, Page(s), Date, Etc.
✓	CP	Gronke et al., "Aspartyl β -hydroxylase: In vitro hydroxylation of a synthetic peptide based on the structure of the first growth factor-like domain of human factor IX", Proc. Natl. Acad. Sci. USA, Vol. 86, May 1989, pp. 3609-3613.
	CQ	Gronke et al., "Partial Purification and Characterization of Bovine Liver Aspartyl β -Hydroxylase", 1990, J. Biol. Chem. 265:8558-8565
	CR	Hagemeijer, "Cytogenetics and oncogenes", Leukemia, November 1992, Vol. 6, Suppl. 4, pp.16-18.
	CS	Hansen T. et al., "Inhibition of insulin receptor phosphorylation by peptides derived from major histocompatibility complex class I antigens," Proc. Natl. Acad. Sci. USA 1989 May ;86 (9):3123-6.
	CT	Higgins et al., "Fast and sensitive multiple sequence alignments on a microcomputer", 1989, CABIOS 5(2):151-153
	CU	Jia et al., "A fully active atalytic domain of bovine aspartyl (asparaginy) β -hydroxylase expressed in Escherichia Coli", Proc. Natl. Acad. Sci. USA 1994 July 19;91(15):7227-31.
	CV	Jia et al., "cDNA Cloning and Expression Bovine Aspartyl (Asparaginy) β -Hydroxylase", 1992, J. Biol. Chem. 267:14322-14327
	CW	Jones et al., "Antibodies for targeting gene therapy", Advanced Drug Delivery Reviews, Apr. 1998, Vol. 31, pp. 153-170.
	CX	Kelley et al., "Mutations Altering the Structure of Epidermal Growth Factor-like Coding Sequences at the Drosophila Notch Locus, Cell., Nov. 20, 1997, Vol. 51, p. 539-548.
	CY	Kieke, et al., "Selection of Functional T Cell Receptor Mutants From a Yeast Surface-Display Library", Proc. Natl. Acad. Sci. USA, May 1999, Vol. 97, 5651-5656
	CZ	Kobayashi et al., "Reversal of Drug Sensitivity in Multidrug-Resistant Tumor Cells by an MDR1 (PGY1) Ribozyme", 1994, Cancer Res. 54:1271-1275
	CAA	Koriath et al., "Cloning and characterization of the human gene encoding aspartyl β -hydroxylase", Gene, 150, 1994, 395-399
	CAB	Lam K., et al., "The Phosphatidylinositol 3-Kinase Serine Kinase Phosphorylates IRS-1", J. Biol. Chem., 1994 August 12;269(32):20648-52
	CAC	Lardelli et al., "The Novel Notch homologue mouse Notch 3 lacks specific epidermal growth factor-repeats and is expressed in proliferating neurothelium", Mechanisms of Development, 46 (1994) 123-136.
	CAD	Lavaissiere et al., "Overexpression of Human Aspartyl (asparaginy) β -Hydroxylase in Hepatocellular Carcinoma and Cholangiocarcinoma", 1996, J. Clin. Invest. 98:1313-1323
✓	CAE	Lecka-Czemik et al., "An Overexpressed Gene Transcript in Senescent and Quiescent Human Fibroblasts Encoding a Novel Protein in the Epidermal Growth Factor-Like Repeat Family Stimulates DNA Synthesis", Molecular and Cellular Biology, Vol. 15, Jan. 1995, p. 120-128.
Examiner Signature		
Date Considered	6/13/03	

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.




INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application Number	09/859,604				
		Filing Date	May 17, 2001				
		First Named Inventor	Jack R. Wands				
		Group Art Unit	Not yet assigned				
		Examiner Name	Not yet assigned				
		Attorney Docket Number	21486-032CIP				
U.S. PATENT DOCUMENTS							
Exam Initials	Cite No.	U.S. Patent Document No.	Issue Date	Name of Patentee(s) or Applicant(s)	Class	Sub Class	Filing Date If Appropriate

OTHER NON PATENT LITERATURE DOCUMENTS				
Exam Initials	Cite No.	Name of Author, Title (when appropriate), Publication, Volume, Page(s), Date, Etc.		
KAL	CAF	Levy-Toledano R. et al., "Investigation of the mechanism of the dominant negative effect of mutations in the tyrosine kinase domain of the insulin receptor, EMBO J. 1994 Feb 15;13(4):825-42.		
	CAG	Li et al., "Modulation of Insulin Receptor Substrate-1 Tyrosine Phosphorylation by an Akt/Phosphatidylinositol 3-Kinase Pathway", J. Biol. Chem., 1999 Apr 2;274 (14):9351-6.		
	CAH	Mahieu et al., "Construction of a Ribozyme Directed Against Human Interleukin-6 mRNA; Evaluation of Its Catalytic Activity In Vitro and In Vivo", 1994, Blood 84:3758-65		
	CAI	Marasco et al., "Design, intracellular expression, and activity of a human anti-human immunodeficiency virus type-1 gp120 single-chain antibody" 1993, Proc. Natl. Acad. Sci. USA 90:7889-7893. (1998) 454-456		
	CAJ	Marasco et al., "Intrabodies: turning the humoral immune system outside in for intracellular immunization", 1997, Gene Therapy 4:11-15		
	CAK	McGinnis et al., "The five cysteine residues located in the active site region of bovine aspartyl β -hydroxylase are not essential for catalysis", Biochemica et Biophysica Acta 1387		
	CAL	McGinnis et al., "Site-Directed Mutagenesis of Residues in a Conserved Region of Bovine Aspartyl β -Hydroxylase: Evidence That Histidine 675 Has a Role in Binding Fe", Biochemistry 1996, 35, 3957-3962.		
	CAM	Rozan F., Pollack, M., "Inhibition of insulin-like growth factor I receptor signaling by the vitamin D analogue EB 1089 in MCF-7 breast cancer cells: A role for insulin-like growth factor binding proteins", Int. J. Oncol., 1999, Sept. 15(3):589-94.		
	CAN	Song et al., "Proteolytic release and nuclear translocation of notch-1 are induced by presenilin-1 and impaired by pathogenic presenilin-1 mutations", 1999, Proc. Natl. Acad. Sci U.S.A. 96:6959-6963		
	CAO	Sullivan et al., "Development of Ribozymes for Gene Therapy", 1994, J. Invest. Derm. 103:85S-89S		
	CAP	Treves, et al. "Molecular Cloning, Expression, Functional Characterization, Chromosomal Localization, and Gene Structure of Junctate, a Novel Integral Calcium Binding Protein of Sarco(endo)plasmic Reticulum Membrane," (2000) 275, 39555-68		
	CAQ	Van de Poll ML et al., "Identification of the Minimal Requirements for Binding to the Human Epidermal Growth Factor (EGF) Receptor Using Chimeras of Human EGF and an EGF Repeat of Drosophila Notch", J. Biol. Chem. 1998 June 26;273(26):16075-81.		
	CAR	Wang et al., "Bovine Liver Aspartyl β -Hydroxylase", 1991, J. Biol. Chem. 266:14004-14010		
	CAS	Zhang et al., "Development of a Carbon Dioxide-Capture Assay in Microtiter Plate for Aspartyl β -Hydroxylase", 1999, Anal. Biochem. 271:137-142		
Examiner Signature		<i>Karen A. Gannell</i>	Date Considered	6/13/03

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Express Mail No.: EL831676380US
Date of Deposit: October 12, 2001

Attorney Docket No.: 21486-032 CIP



FORM PTO-1449(Modified) LIST OF PATENTS AND PUBLICATIONS FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT "Diagnosis and Treatment of Malignant Neoplasms"	ATTY. DOCKET NO. 21486-032 CIP	SERIAL NO. 09/859,604
	FIRST NAMED APPLICANT: Wands	
	FILING DATE: May 17, 2001	GROUP: 1642

U.S. PATENT DOCUMENTS

Exam Init	Ref Des	Document No.	Date	Name	Class	Sub Class	FILING DATE If Appropriate
KAC	A2	US 6,166,176	12/26/00	Radosevich			03/17/98

FOREIGN PATENT DOCUMENTS

	Country & Doc. No. (11)	Pub. Date (43)	Class	Sub Class	Translation Yes No

OTHER ART

(Including Author, Title, Date, Pertinent Pages, Publication, Etc.)

KAC	C46	Ausebel, F. et al. <u>Current Protocols in Molecular Biology</u> , Vol. 2 1990. John Wiley & Sons.
	C47	De La Monte, S. et al. (1999). <u>Modern Pathology</u> 12: 170A.
	C48	Ghose, T. et al. (1983). <u>Methods in Enzymology</u> 93: 280-333.
	C49	Gual, P. et al. (1996). <u>Endocrinology</u> 137: 3416-2423.
	C50	Ince, N. et al. (1997). <u>Hepatology</u> 26(4): 362A.
	C51	Ince, N. et al. (2000). <u>Cancer Research</u> 60: 1261-1266.
	C52	Nishimaki, H. et al. (1999). <u>Jikeikai Medical Journal</u> 46: 129-136.
✓	C53	Nishimaki, H. et al. (1997). <u>Gastroenterology</u> 112(4)Supp.: A628.
	C54	International Search Report, issued June 5, 2001.

*A copy of this reference is not provided as it was previously cited by or submitted to the office in a prior application, Serial No. _____, filed _____, since abandoned, and relied upon for an earlier filing date under 35 U.S.C. 120 (continuation, continuation-in-part, and divisional applications).

EXAMINER <i>Karen A. Gancille</i>	DATE CONSIDERED <i>6/13/03</i>
--------------------------------------	-----------------------------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw a line through citation if not in conformance and not considered.

Please include copy of this form with next communication to applicant